TJ-C4GM

TJ-C4GM is an investigational **CD47-targeted engineered immuno-oncology biologic** being developed by I-Mab for **solid tumors**. Public pipeline descriptions characterize it as a **fortified anti-CD47 antibody with GM-CSF attached**, intended to enhance antitumor activity beyond a standalone CD47 antibody by combining **CD47 blockade** with **GM-CSF mediated myeloid activation and macrophage repolarization**, including promotion of conversion of pro-tumor M2 macrophages toward anti-tumor M1 macrophages. Available public information consistently places the program in **preclinical development**, and the construct is described in company-facing materials as part of I-Mab's next-generation bispecific or antibody-cytokine immunotherapy pipeline for oncology.

Other names

TJ C4GM